Evaluation of Potential Predictors of Adherence by Investigating a Representative Cohort of Multiple Sclerosis (MS) Patients in Germany Treated With Betaferon (BETAPREDICT)

Bayer

Status: Completed

Conditions: Multiple Sclerosis

Treatments: Drug: Interferon beta-1b (Betaferon, BAY86-5046); Device: Betaconnect Autoinjector

Study type: Observational

Funder types: Industry

Identifiers

NCT02486640

BF1502 (Registry Identifier)

18016

Details and patient eligibility

About

This study aims to evaluate potential predictors of adherence by investigating a representative cohort of MS patients in Germany treated with Betaferon

Enrollment: 162 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients aged ≥ 18 years with the diagnosis of relapsing remitting multiple sclerosis or a clinically isolated syndrome
• Patients on treatment with Betaferon or the decision to treat patients with Betaferon has been made by the attending physician
• Patients using or willing to use the BETACONNECT autoinjector for Betaferon application
• Written informed consent

Exclusion criteria

• Patients receiving any other disease modifying drug
• Contraindications of Betaferon described in the Summary of Product Characteristics
• Patients participating in any other clinical or non-interventional study, evaluating MS therapy

Trial design

162 participants in 1 patient group

Betaferon

Treatment:

Device: Betaconnect Autoinjector

Drug: Interferon beta-1b (Betaferon, BAY86-5046)